An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27 to 30, 2021. On September 29 at 10:40 AM ET, CEO Bruce Steel and CMO Dolca Thomas will discuss itolizumab's mechanism and ongoing clinical programs, particularly its Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD).
A live webcast will be available at Equillium's website, with an archived replay for 90 days.
Positive
None.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference, taking place September 27 – 30, 2021.
Bruce Steel, Equillium’s chief executive officer, and Dolca Thomas M.D., Equillium’s executive vice president of research and development and chief medical officer, will provide a high-level overview of itolizumab’s mechanism of action and review each of the ongoing clinical programs. The presentation will focus on topline data from the company’s Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD) and recent regulatory feedback leading directly to a pivotal Phase 3 study in aGVHD, expected to be initiated before the end of 2021. Mr. Steel, Dr. Thomas and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference.
Date: Wednesday, September 29, 2021 Time: 10:40 AM Eastern Time | 7:40 AM Pacific Time Location: Virtual Webcast
A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
What is Equillium's participation in the Cantor Fitzgerald conference?
Equillium will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27 to 30, 2021.
When will Equillium's presentation take place?
Equillium's presentation is scheduled for September 29, 2021, at 10:40 AM Eastern Time.
Who will represent Equillium at the conference?
CEO Bruce Steel and CMO Dolca Thomas will represent Equillium at the conference.
What will Equillium discuss during the presentation?
Equillium will discuss the mechanism of action of itolizumab and ongoing clinical programs, focusing on the Phase 1b EQUATE study in acute graft-versus-host disease.
Where can I watch Equillium's presentation?
The presentation will be available live on Equillium's website in the 'Investors' section, with a replay accessible for 90 days.
